1. Mossinghoff, G. J. Food Drug Law J. 54, 187–194 (1999).
2. Dunn, M. K. Nat. Rev. Drug Discov. 10, 487–488 (2011).
3. Pew Charitable Trusts. Policy proposal: reducing the exclusivity period for biological products.
https://www.pewtrusts.org/-/media/assets/2017/09/dsri_policy_proposal_reducing_the_exclusivity_period_for_biological_products.pdf
(2017).
4. Husser, A. Will USMCA affect Canada’s drug prices? Depends on what happens next, experts say.
https://www.cbc.ca/news/health/usmca-pharma-drugs-prices-cost-1.4846421
(2018).
5. PhRMA. Response to request for comments on negotiating objectives for a U.S.–Japan trade agreement, 83 Fed. Reg. 54,164 (October 26, 2018).
http://phrma-docs.phrma.org/files/dmfile/PhRMA-Comments-on-Negotiating-Objectives-for-U.S.-Japan-Trade-Agreement.pdf
(2018).